Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

Overexpression of alpha-synuclein can cause Parkinson's

Researchers at the University of California, San Diego School of Medicine say overexpression of a protein called alpha-synuclein appears to disrupt vital recycling processes in neurons, starting with the terminal extensions of neurons and working its way back to the cells' center, with the potential consequence of progressive degeneration and eventual cell death.

10 Feb 2013

Drugs that target retromer pathway could help prevent or treat Parkinson's

Columbia University Medical Center (CUMC) researchers have identified a protein trafficking defect within brain cells that may underlie common non-familial forms of Parkinson's disease.

9 Feb 2013

Nerve stimulator may be new option for migraine sufferers

Wearing a nerve stimulator for 20 minutes a day may be a new option for migraine sufferers, according to new research published in the February 6, 2013, online issue of Neurology, the medical journal of the American Academy of Neurology.

9 Feb 2013

Studies to identify molecular causes and preventive and therapeutic strategies for Parkinson's

On the fourth floor of Wichita State University's McKinley Hall, biochemistry professor Kandatege Wimalasena and his group of doctoral and undergraduate students are hard at work researching Parkinson's disease (PD) - the second-most common neurodegenerative disease, affecting 1 to 2 percent of people older than 60.

7 Feb 2013

Occupational exposure to magnetic fields may moderately increase risk of Alzheimer's, ALS

Occupational exposure to magnetic fields (MF) may be associated with "moderately increased risk" of certain neurodegenerative diseases—including Alzheimer's and amyotrophic lateral sclerosis, reports the February Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM).

7 Feb 2013

Teva initiates enrollment in AZILECT Phase IV clinical study for PD-MCI

Teva Pharmaceutical Industries Ltd. announced today enrollment of the first patient in the MODERATO study - a Phase IV clinical study designed to evaluate the effect of AZILECT (rasagiline tablets) on cognitive function in adults with mild cognitive impairment (MCI) in Parkinson's disease (PD-MCI).

6 Feb 2013

NSU-COM to hold grand opening for America's first Institute for Neuro Immune Medicine

Nova Southeastern University's College of Osteopathic Medicine (NSU-COM) will hold a grand opening for America's first Institute for Neuro Immune Medicine on Feb. 12.

5 Feb 2013

Scientists receive honorary doctorate for research on Alzheimer's disease

On Monday 4 February, Dennis J. Selkoe and five other "brain teasers" will receive an honorary doctorate from the KU Leuven. The promoters for this honorary doctorate - VIB-KU Leuven professors Bart De Strooper and Wim Robberecht - will honor Dennis J. Selkoe for his scientific insights, but also for his relentless search for new medicines to treat Alzheimer's Disease and other conditions that cause severe damage in the brain.

4 Feb 2013

Study investigates R1441G mutation of Parkinson's disease

A team from the UPV/EHU-University of the Basque Country came across a mutation of the LRRK2 gene in 2004, which is particularly prevalent among the population of Gipuzkoa. It is the R1441G mutation and is known as the Basque mutation.

1 Feb 2013

Weill Cornell and NewYork-Presbyterian create pioneering Institute for Precision Medicine

Recognizing that medicine is not "one size fits all," Weill Cornell Medical College and NewYork-Presbyterian Hospital have created the pioneering Institute for Precision Medicine at Weill Cornell and NewYork-Presbyterian/Weill Cornell Medical Center. This new, cutting-edge translational medicine research hub will explore the new frontier of precision medicine, offering optimal targeted, individualized treatment based on each patient's genetic profile.

1 Feb 2013

Feinstein Institute, Merck Serono to develop antibodies for treatment of SLE

Merck Serono, a division of Merck, Darmstadt, Germany, and The Feinstein Institute for Medical Research, announced today that they will collaborate to develop antibodies for the treatment of systemic lupus erythematosus (SLE).

30 Jan 2013

Hydrogen sulfide may play a wide-ranging role in staving off aging

Hydrogen sulfide (H2S) may play a wide-ranging role in staving off aging, according to a paper published online ahead of print in the journal Molecular and Cellular Biology.

30 Jan 2013

Insight into reasons why precocious puberty occurs in females

New research from Oregon Health & Science University has provided significant insight into the reasons why early-onset puberty occurs in females.

30 Jan 2013

Sanofi announces availability of Auvi-Q in U.S. retail pharmacies

Sanofi announced today that Auvi-Q (epinephrine injection, USP) is now available in U.S. retail pharmacies nationwide with a prescription from a healthcare provider.

29 Jan 2013

UMDNJ-School of Osteopathic Medicine to develop blood test that can diagnose MCI

The Biomarker Discovery Center at the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine has been awarded a three-year, $799,800 grant from the Osteopathic Heritage Foundation to develop a blood test that can diagnose mild cognitive impairment (MCI) caused by early-stage Alzheimer's disease.

28 Jan 2013